Log In Sign up
The largest database of trusted experimental protocols

Trametinib

Manufactured by Axon Medchem
Visit Supplier

Trametinib is a laboratory equipment product designed for use in scientific research and experiments. It is a selective inhibitor of the MEK1 and MEK2 enzymes, which are part of the MAPK/ERK signaling pathway. Trametinib is commonly used in research settings to study cellular processes and signal transduction mechanisms.

Automatically generated - may contain errors

Lab products found in correlation

Dabrafenib, by Selleck Chemicals (1 mentions) Pd0325901, by Selleck Chemicals (1 mentions) Sch772984, by Selleck Chemicals (1 mentions) Lorlatinib, by Pfizer (1 mentions) Ly3009120, by Selleck Chemicals (1 mentions) Rapamycin, by Axon Medchem (1 mentions)

2 protocols using trametinib

1

Investigating Inhibitors in Cancer Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
OTSSP167 hydrochloride was purchased from Medchem Express; trametinib was obtained from Axon Medchem; PD0325901, SCH772984, and dabrafenib were from Selleckchem. For in vitro experiments, drugs were dissolved in 100% dimethyl sulfoxide (DMSO), and a maximum final concentration of 0.1% DMSO was allowed during experiments. For in vivo experiments, drugs were dissolved in NaCl 0.9% containing a final concentration of 10% DMSO.
Meel M.H., Guillén Navarro M., de Gooijer M.C., Metselaar D.S., Waranecki P., Breur M., Lagerweij T., Wedekind L.E., Koster J., van de Wetering M.D., Schouten-van Meeteren N., Aronica E., van Tellingen O., Bugiani M., Phoenix T.N., Kaspers G.J, & Hulleman E. (2019). MEK/MELK inhibition and blood–brain barrier deficiencies in atypical teratoid/rhabdoid tumors. Neuro-Oncology, 22(1), 58-69.
+ Open protocol
+ Expand
2

Evaluation of Targeted Cancer Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lorlatinib, ceritinib, trametinib, rapamycin and pictilisib were purchased from Axon Medchem (#Axon2600, #Axon224, #Axon1761, #Axon2069, #Axon1377). Lorlatinib was given from Pfizer for in vivo studies with the NBLW-R. LY3009120 was bought from Selleck Chemicals (#S7842).
Berlak M., Tucker E., Dorel M., Winkler A., McGearey A., Rodriguez-Fos E., da Costa B.M., Barker K., Fyle E., Calton E., Eising S., Ober K., Hughes D., Koutroumanidou E., Carter P., Stankunaite R., Proszek P., Jain N., Rosswog C., Dorado-Garcia H., Molenaar J.J., Hubank M., Barone G., Anderson J., Lang P., Deubzer H.E., Künkele A., Fischer M., Eggert A., Kloft C., Henssen A.G., Boettcher M., Hertwig F., Blüthgen N., Chesler L, & Schulte J.H. (2022). Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Molecular Cancer, 21, 126.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!